Compounded vs. Brand-Name GLP-1s: What's Actually Different
A plain-language guide to how compounded semaglutide and tirzepatide differ from their FDA-approved counterparts — in the evidence behind them, the oversight they get, and the risks they carry.
By Wellness Wire Editorial
GLP-1 medications for weight loss and diabetes have become some of the most talked-about drugs in years — and, during recent shortages, some of the hardest to get. Many people turned to "compounded" versions mixed by pharmacies rather than the brand-name products from their manufacturers. The active ingredient may carry the same name, but compounded and brand-name GLP-1s are not interchangeable in the ways that matter most: the evidence behind them, the oversight they receive, and the risks they carry. Here is what the available evidence actually shows — and where it runs out.
Start with the vocabulary
Brand-name GLP-1s are specific, FDA-approved finished products: once-weekly semaglutide (sold as Wegovy for weight management and Ozempic for diabetes) and tirzepatide (Zepbound and Mounjaro). Compounded GLP-1s are made by pharmacies that mix the drug themselves. Two very different kinds of facility do this, and the distinction drives much of the quality-control debate.
- 503A compounding pharmacies fill patient-specific prescriptions, are overseen mainly by state boards under the USP <795> and <797> standards, and are not required to follow federal current good manufacturing practice (CGMP) rules.
- 503B outsourcing facilities can make larger batches without a prescription for each patient, but they must register with the FDA, submit to FDA inspection, and comply with CGMP (21 CFR parts 210 and 211).
Neither type submits its product for the FDA premarket review that brand-name drugs must pass. That review — for safety, effectiveness, and quality — is the central thing compounded versions lack, and it is why the FDA says compounded drugs pose a higher risk to patients than approved ones.
What the brand-name trials proved
The FDA-approved products are backed by large randomized trials. Those trials are the reason we can speak with any confidence about how well the brand-name drugs work — and every figure below was measured on an approved product, not on a compounded copy.
- STEP 1Once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% at 68 weeks, versus -2.4% for placebo (n=1,961). Some 86.4% of people on semaglutide lost at least 5% of their weight, versus 31.5% on placebo. This is the pivotal evidence for the approved drug (Wegovy).
- SURMOUNT-1Tirzepatide reduced weight by 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses at 72 weeks, versus 3.1% for placebo (n=2,539 adults with obesity, without diabetes).
- SELECTAmong 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, semaglutide 2.4 mg cut major cardiovascular events to 6.5% versus 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72–0.90) — about a 20% relative reduction.
- SURMOUNT-OSATirzepatide substantially reduced the apnea-hypopnea index — on the order of 20 to 25 fewer breathing events per hour than placebo across its two parallel trials — with roughly 17–20% weight loss, supporting an FDA approval for obstructive sleep apnea.
These two molecules are not the same drug. In the head-to-head SURPASS-2 trial in type 2 diabetes, tirzepatide produced larger reductions in A1C and body weight than semaglutide 1 mg — roughly -2.1% to -2.5% A1C for tirzepatide versus about -1.9% for semaglutide. Tirzepatide acts on two gut-hormone receptors (GIP and GLP-1); semaglutide acts on one (GLP-1). Molecule, dose, and formulation are not interchangeable details.
Every one of these results describes an FDA-approved product. None of it was measured on a compounded copy.
Same name, not the same evidence
Here is the crucial gap: no comparable randomized trials exist for compounded GLP-1s. Even when a compounded product's active ingredient carries the same name, its efficacy and safety cannot simply be assumed to match the brand — the weight-loss, cardiovascular, and sleep-apnea results above were measured on the approved drugs, not on copies of them. Compounded versions have no such outcomes data of their own, and none are approved or tested for indications like obstructive sleep apnea.
Compounding can also introduce a subtler difference. Some pharmacies have used unapproved "salt" forms of semaglutide (such as semaglutide sodium or acetate), which are not the same active ingredient as the approved base. This is a documented concern raised by the FDA and state pharmacy boards — not a claim that all compounded product is adulterated, but a reason the word "semaglutide" on a label does not guarantee sameness.
Safety concerns regulators have flagged
The FDA's position is that compounded drugs carry higher risk than approved ones precisely because they skip premarket review for safety, effectiveness, and quality. The agency has specifically warned about overdoses from dosing errors with compounded injectable semaglutide: patients and providers miscalculating milligram-to-unit or milligram-to-milliliter conversions, and drawing doses from multidose vials — in some cases taking 5 to 10 times the intended amount and ending up hospitalized.
By early 2025, regulators had logged more than 400 adverse-event reports tied to compounded semaglutide and more than 300 tied to compounded tirzepatide. These are spontaneous reports: they establish that harms were reported, but they do not by themselves measure how often problems occur or prove the compounded drug caused them. Treat them as a signal worth taking seriously, not a precise risk estimate.
The legal picture is shifting
Large-scale compounding of GLP-1s was permitted largely because the brand-name drugs were in shortage. The FDA has since declared those shortages resolved — tirzepatide was removed from the shortage list in October 2024 (reaffirmed December 19, 2024), and semaglutide was marked resolved on February 21, 2025 — and set wind-down deadlines through the spring of 2025 (tirzepatide: 503A pharmacies by February 18 and 503B facilities by March 19, 2025; semaglutide: 503A by April 22 and 503B by May 22, 2025). Once a drug is off the shortage list, large-scale compounding of "essentially a copy" is no longer permitted.
As of April 30, 2026, the agency went further, proposing to remove GLP-1 receptor agonists (semaglutide, tirzepatide, and liraglutide) from the 503B "bulks" list. If finalized after a public comment period that ran through June 2026, that would bar outsourcing facilities from bulk-compounding these drugs even in a future shortage, citing no current clinical need and greater risk of adverse events, safety concerns, and product-quality issues. That picture is still moving: with the comment period closed and litigation over the FDA's shortage decisions ongoing, whether a given compounded GLP-1 is legal to make may look different by the time you read this.
The bottom line
So what is actually different? The active ingredient may share a name, but the brand-name GLP-1s come with large randomized trials, FDA premarket review, and — for the approved products — documented benefits ranging from substantial weight loss to fewer cardiovascular events. Compounded versions come with none of those guarantees, more variability in how they are made, a documented dosing-error risk, and a legal status that is shifting. That does not make every compounded dose dangerous, and cost and access are real considerations for many people. But "same molecule" is not the same as "same evidence" or "same oversight" — and that gap is the honest answer to what's different. Anyone weighing the two should have that conversation with a licensed clinician who knows their history.
- 01 Pivotal semaglutide 2.4 mg weight-loss trial results for the approved drug.
- 02 PubMed / New England Journal of Medicine — SURMOUNT-1 (Jastreboff et al.), 2022 pubmed.ncbi.nlm.nih.gov ↗Pivotal tirzepatide obesity trial (5/10/15 mg weight reductions).
- 03 Semaglutide 2.4 mg cardiovascular-outcomes trial in adults with CVD, without diabetes.
- 04 Radcliffe Cardiology — SURMOUNT-OSA coverage (Malhotra et al., NEJM), 2024 radcliffecardiology.com ↗Tirzepatide for obstructive sleep apnea with obesity; apnea-hypopnea index reductions.
- 05 Head-to-head tirzepatide vs semaglutide 1 mg in type 2 diabetes (A1C and weight).
- 06 McDermott Will & Emery — 'Semaglutide Shortage Resolved', 2025 mcdermottlaw.com ↗Shortage-resolution dates and compounding wind-down enforcement deadlines.
- 07 The FDA Group — '503A vs. 503B: A Quick-Guide to Compounding Pharmacy Designations & Regulations', 2024 thefdagroup.com ↗Structural differences in oversight and CGMP requirements between 503A and 503B.
- 08 Higher-risk warning and overdoses from mg-to-unit/mL conversion errors.
- 09 Medical News Today — 'FDA moves to remove GLP-1 medications from 503B Bulks List', 2026 medicalnewstoday.com ↗April 30, 2026 proposal and comment period on removing GLP-1s from the 503B bulks list.
Wellness Wire Editorial
The Wellness Wire editorial team. Our explainers are researched from primary sources — clinical-trial reports and FDA labeling — and written for general education. They are not individually reviewed by a clinician and are not a substitute for medical advice.
